Details of the Drug Reposition

General Information of This Drug (ID: DMP36KD)

• Drug Name: MLN4924 (DMP36KD)
• Synonyms: Pevonedistat; 905579-51-3; MLN4924; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Myelodysplastic syndrome	DISYHNUI	2A37	Phase 3	[1]

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Acute myelogenous leukaemia	DISCSPTN	2A41	Phase 2	[2]

1 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Advanced malignancy	DISAB5B8	2A00-2F9Z	Phase 1	[3]

1 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Nasopharyngeal carcinoma	DISAOTQ0	2B6B	Investigative	[4]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Drug discovery: Fresh target for cancer therapy. Nature. 2009 Apr 9;458(7239):709-10.
• [4] Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target.Cell Death Dis. 2017 Jun 1;8(6):e2834.